Transcode Historical Financial Ratios

RNAZ Stock

USD 0.49 0.03 5.77%

Transcode Therapeutics is promptly reporting on over 88 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Book Value Per Share of 7.84, Invested Capital of 0.0, Average Payables of 1.7 M or Stock Based Compensation To Revenue of 0.0 will help investors to properly organize and evaluate Transcode Therapeutics financial condition quickly.

Quick Ratio Current Ratio

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Transcode Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy Transcode Stock please use our How to Invest in Transcode Therapeutics guide.

About Transcode Financial Ratios Analysis

Transcode TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Transcode Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Transcode financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Transcode Therapeutics history.

Transcode Therapeutics Financial Ratios Chart

At this time, Transcode Therapeutics' Total Debt To Capitalization is fairly stable compared to the past year.

Average Payables Inventory Turnover Days Of Inventory On Hand Payables Turnover

Add Fundamental

Average Payables

The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.

Inventory Turnover

A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.

Payables Turnover

A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.

Most ratios from Transcode Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Transcode Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Transcode Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy Transcode Stock please use our How to Invest in Transcode Therapeutics guide.At this time, Transcode Therapeutics' Total Debt To Capitalization is fairly stable compared to the past year.

	2010	2024	2025 (projected)
Payables Turnover	0.0211	0.0204	0.0175
Days Of Inventory On Hand	2.1K	1.8K	1.6K

Payables Turnover Days Of Inventory On Hand

Transcode Therapeutics fundamentals Correlations

	Ptb Ratio	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Average Payables	Capex To Depreciation	Pb Ratio	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow	Pe Ratio	Return On Tangible Assets	Ev To Free Cash Flow	Earnings Yield
Ptb Ratio		0.38	-0.65	-0.56	0.7	-0.62	1.0	-0.56	-0.66	-0.45	-0.49	-0.46	-0.07	0.38	0.96	-0.65	0.75	0.96	-0.04	0.27	-0.78	0.95	1.0	-0.53	0.95	-0.68
Book Value Per Share	0.38		0.03	-0.5	0.02	0.04	0.38	-0.52	0.12	0.03	-0.31	0.03	0.04	0.97	0.45	-0.05	0.0	0.45	-0.05	0.3	-0.05	0.48	0.36	0.44	0.48	0.02
Free Cash Flow Yield	-0.65	0.03		-0.01	-0.71	1.0	-0.65	-0.01	0.8	0.76	-0.07	0.76	0.37	0.15	-0.73	0.99	-0.89	-0.73	-0.3	-0.36	0.89	-0.73	-0.68	0.64	-0.73	1.0
Operating Cash Flow Per Share	-0.56	-0.5	-0.01		-0.52	-0.07	-0.56	1.0	0.43	-0.04	0.97	-0.04	-0.34	-0.5	-0.59	-0.04	-0.4	-0.59	0.46	-0.38	0.42	-0.59	-0.54	0.26	-0.59	0.07
Average Payables	0.7	0.02	-0.71	-0.52		-0.68	0.7	-0.52	-0.91	-0.27	-0.52	-0.28	0.28	-0.07	0.78	-0.66	0.91	0.78	-0.31	0.62	-0.9	0.77	0.72	-0.73	0.77	-0.76
Capex To Depreciation	-0.62	0.04	1.0	-0.07	-0.68		-0.62	-0.07	0.76	0.73	-0.14	0.74	0.36	0.16	-0.7	0.99	-0.86	-0.7	-0.28	-0.34	0.86	-0.69	-0.65	0.6	-0.69	0.99
Pb Ratio	1.0	0.38	-0.65	-0.56	0.7	-0.62		-0.56	-0.66	-0.45	-0.49	-0.46	-0.07	0.38	0.96	-0.65	0.75	0.96	-0.04	0.27	-0.78	0.95	1.0	-0.53	0.95	-0.68
Free Cash Flow Per Share	-0.56	-0.52	-0.01	1.0	-0.52	-0.07	-0.56		0.42	-0.04	0.97	-0.04	-0.34	-0.52	-0.59	-0.04	-0.39	-0.59	0.45	-0.38	0.41	-0.6	-0.55	0.25	-0.6	0.06
Roic	-0.66	0.12	0.8	0.43	-0.91	0.76	-0.66	0.42		0.59	0.43	0.59	0.09	0.23	-0.76	0.74	-0.97	-0.76	0.04	-0.53	0.96	-0.75	-0.68	0.89	-0.75	0.85
Inventory Turnover	-0.45	0.03	0.76	-0.04	-0.27	0.73	-0.45	-0.04	0.59		-0.1	1.0	0.85	0.12	-0.52	0.76	-0.63	-0.52	-0.66	0.04	0.65	-0.51	-0.48	0.52	-0.51	0.75
Net Income Per Share	-0.49	-0.31	-0.07	0.97	-0.52	-0.14	-0.49	0.97	0.43	-0.1		-0.1	-0.39	-0.33	-0.48	-0.13	-0.36	-0.48	0.51	-0.27	0.37	-0.48	-0.48	0.34	-0.48	0.0
Days Of Inventory On Hand	-0.46	0.03	0.76	-0.04	-0.28	0.74	-0.46	-0.04	0.59	1.0	-0.1		0.84	0.12	-0.52	0.76	-0.64	-0.52	-0.67	0.03	0.66	-0.51	-0.48	0.53	-0.51	0.76
Payables Turnover	-0.07	0.04	0.37	-0.34	0.28	0.36	-0.07	-0.34	0.09	0.85	-0.39	0.84		0.08	-0.09	0.39	-0.13	-0.09	-0.85	0.38	0.15	-0.08	-0.08	0.12	-0.08	0.33
Cash Per Share	0.38	0.97	0.15	-0.5	-0.07	0.16	0.38	-0.52	0.23	0.12	-0.33	0.12	0.08		0.39	0.07	-0.11	0.39	-0.07	0.13	0.06	0.41	0.37	0.5	0.41	0.14
Pocfratio	0.96	0.45	-0.73	-0.59	0.78	-0.7	0.96	-0.59	-0.76	-0.52	-0.48	-0.52	-0.09	0.39		-0.74	0.84	1.0	-0.04	0.49	-0.87	1.0	0.96	-0.55	1.0	-0.77
Interest Coverage	-0.65	-0.05	0.99	-0.04	-0.66	0.99	-0.65	-0.04	0.74	0.76	-0.13	0.76	0.39	0.07	-0.74		-0.85	-0.74	-0.33	-0.35	0.86	-0.73	-0.68	0.56	-0.73	0.98
Capex To Operating Cash Flow	0.75	0.0	-0.89	-0.4	0.91	-0.86	0.75	-0.39	-0.97	-0.63	-0.36	-0.64	-0.13	-0.11	0.84	-0.85		0.84	-0.01	0.48	-1.0	0.83	0.78	-0.8	0.83	-0.92
Pfcf Ratio	0.96	0.45	-0.73	-0.59	0.78	-0.7	0.96	-0.59	-0.76	-0.52	-0.48	-0.52	-0.09	0.39	1.0	-0.74	0.84		-0.04	0.49	-0.87	1.0	0.96	-0.55	1.0	-0.77
Days Payables Outstanding	-0.04	-0.05	-0.3	0.46	-0.31	-0.28	-0.04	0.45	0.04	-0.66	0.51	-0.67	-0.85	-0.07	-0.04	-0.33	-0.01	-0.04		-0.32	-0.03	-0.04	-0.03	0.01	-0.04	-0.25
Income Quality	0.27	0.3	-0.36	-0.38	0.62	-0.34	0.27	-0.38	-0.53	0.04	-0.27	0.03	0.38	0.13	0.49	-0.35	0.48	0.49	-0.32		-0.48	0.49	0.25	-0.32	0.49	-0.38
Roe	-0.78	-0.05	0.89	0.42	-0.9	0.86	-0.78	0.41	0.96	0.65	0.37	0.66	0.15	0.06	-0.87	0.86	-1.0	-0.87	-0.03	-0.48		-0.86	-0.8	0.78	-0.86	0.93
Ev To Operating Cash Flow	0.95	0.48	-0.73	-0.59	0.77	-0.69	0.95	-0.6	-0.75	-0.51	-0.48	-0.51	-0.08	0.41	1.0	-0.73	0.83	1.0	-0.04	0.49	-0.86		0.95	-0.53	1.0	-0.76
Pe Ratio	1.0	0.36	-0.68	-0.54	0.72	-0.65	1.0	-0.55	-0.68	-0.48	-0.48	-0.48	-0.08	0.37	0.96	-0.68	0.78	0.96	-0.03	0.25	-0.8	0.95		-0.54	0.95	-0.71
Return On Tangible Assets	-0.53	0.44	0.64	0.26	-0.73	0.6	-0.53	0.25	0.89	0.52	0.34	0.53	0.12	0.5	-0.55	0.56	-0.8	-0.55	0.01	-0.32	0.78	-0.53	-0.54		-0.53	0.68
Ev To Free Cash Flow	0.95	0.48	-0.73	-0.59	0.77	-0.69	0.95	-0.6	-0.75	-0.51	-0.48	-0.51	-0.08	0.41	1.0	-0.73	0.83	1.0	-0.04	0.49	-0.86	1.0	0.95	-0.53		-0.76
Earnings Yield	-0.68	0.02	1.0	0.07	-0.76	0.99	-0.68	0.06	0.85	0.75	0.0	0.76	0.33	0.14	-0.77	0.98	-0.92	-0.77	-0.25	-0.38	0.93	-0.76	-0.71	0.68	-0.76

Click cells to compare fundamentals

Transcode Therapeutics Account Relationship Matchups

Transcode Therapeutics fundamentals Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Ptb Ratio	(8.17)	0.87	2.19	0.59	0.53	0.56
Book Value Per Share	(427.15)	1.9K	202.54	9.17	8.25	7.84
Free Cash Flow Yield	(0.0177)	(0.31)	(2.23)	(18.6)	(21.39)	(20.32)
Operating Cash Flow Per Share	(61.78)	(500.08)	(985.16)	(100.98)	(116.12)	(121.93)
Pb Ratio	(8.17)	0.87	2.19	0.59	0.53	0.56
Free Cash Flow Per Share	(61.78)	(524.28)	(991.46)	(101.17)	(116.35)	(122.17)
Roic	(1.3)	(0.31)	(11.52)	(9.29)	(10.68)	(10.14)
Net Income Per Share	(343.19)	(658.8)	(2.2K)	(103.61)	(119.15)	(125.11)
Cash Per Share	103.77	2.0K	310.53	15.46	13.92	13.22
Pocfratio	(56.51)	(3.35)	(0.45)	(0.0539)	(0.0485)	(0.0509)
Interest Coverage	(1.84)	(64.7)	(1.06)	(383.66)	(441.21)	(419.15)
Pfcf Ratio	(56.51)	(3.2)	(0.45)	(0.0538)	(0.0484)	(0.0508)
Income Quality	0.21	0.77	0.9	0.97	0.88	0.58
Roe	0.8	(0.34)	(10.84)	(11.3)	(13.0)	(12.35)
Ev To Operating Cash Flow	(59.06)	0.6	(0.14)	0.0743	0.0669	0.0702
Pe Ratio	(10.17)	(2.54)	(0.2)	(0.0525)	(0.0473)	(0.0496)
Return On Tangible Assets	(2.59)	(0.3)	(4.63)	(3.59)	(4.13)	(4.33)
Ev To Free Cash Flow	(59.06)	0.57	(0.13)	0.0742	0.0668	0.0701
Earnings Yield	(0.0983)	(0.39)	(4.94)	(19.05)	(21.9)	(20.81)
Current Ratio	2.05	8.97	1.7	1.28	1.47	1.39
Tangible Book Value Per Share	(427.15)	1.9K	202.54	9.17	8.25	7.84
Shareholders Equity Per Share	(427.15)	1.9K	202.54	9.17	8.25	7.84
Graham Net Net	(455.64)	1.7K	73.03	(4.25)	(3.83)	(3.64)
Interest Debt Per Share	310.97	9.03	1.1K	2.8	2.52	2.39
Price Earnings Ratio	(10.17)	(2.54)	(0.2)	(0.0525)	(0.0473)	(0.0496)
Price Book Value Ratio	(8.17)	0.87	2.19	0.59	0.53	0.56
Price Earnings To Growth Ratio	(0.0542)	(0.0277)	(8.67E-4)	5.51E-4	4.96E-4	5.21E-4
Price To Operating Cash Flows Ratio	(56.51)	(3.35)	(0.45)	(0.0539)	(0.0485)	(0.0509)
Price To Free Cash Flows Ratio	(56.51)	(3.2)	(0.45)	(0.0538)	(0.0484)	(0.0508)
Ebt Per Ebit	3.23	1.11	0.94	0.96	1.1	1.61
Company Equity Multiplier	(0.31)	1.12	2.34	3.15	2.84	2.98

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Transcode Stock Analysis

When running Transcode Therapeutics' price analysis, check to measure Transcode Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transcode Therapeutics is operating at the current time. Most of Transcode Therapeutics' value examination focuses on studying past and present price action to predict the probability of Transcode Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transcode Therapeutics' price. Additionally, you may evaluate how the addition of Transcode Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Shareholders Equity Per Share	Debt To Equity
Capex Per Share	Graham Net Net
Average Receivables	Revenue Per Share
Interest Debt Per Share	Debt To Assets
Enterprise Value Over E B I T D A	Short Term Coverage Ratios
Price Earnings Ratio	Operating Cycle
Price Book Value Ratio	Price Earnings To Growth Ratio
Days Of Payables Outstanding	Dividend Payout Ratio
Price To Operating Cash Flows Ratio	Price To Free Cash Flows Ratio
Pretax Profit Margin	Ebt Per Ebit
Operating Profit Margin	Effective Tax Rate
Company Equity Multiplier	Long Term Debt To Capitalization
Total Debt To Capitalization	Return On Capital Employed
Debt Equity Ratio	Ebit Per Revenue
Quick Ratio	Dividend Paid And Capex Coverage Ratio
Net Income Per E B T	Cash Ratio
Cash Conversion Cycle	Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding	Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio	Cash Flow Coverage Ratios
Price To Book Ratio	Fixed Asset Turnover
Capital Expenditure Coverage Ratio	Price Cash Flow Ratio
Enterprise Value Multiple	Debt Ratio
Cash Flow To Debt Ratio	Price Sales Ratio
Return On Assets	Asset Turnover
Net Profit Margin	Gross Profit Margin
Price Fair Value	Return On Equity

Transcode Historical Financial Ratios

About Transcode Financial Ratios Analysis

Transcode Therapeutics Financial Ratios Chart

Average Payables

Inventory Turnover

Payables Turnover

Transcode Therapeutics fundamentals Correlations

Transcode Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Transcode Therapeutics fundamentals Accounts

Also Currently Popular

Additional Tools for Transcode Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Pb Ratio	+ 1.0	Ptb Ratio
Pe Ratio	+ 1.0	Ptb Ratio
Capex To Depreciation	+ 1.0	Free Cash Flow Yield
Earnings Yield	+ 1.0	Free Cash Flow Yield
Free Cash Flow Per Share	+ 1.0	Operating Cash Flow Per Share
Pe Ratio	+ 1.0	Pb Ratio

Roe	- 1.0	Capex To Operating Cash Flow
Capex To Operating Cash Flow	- 0.97	Roic
Earnings Yield	- 0.92	Capex To Operating Cash Flow
Roic	- 0.91	Average Payables
Roe	- 0.9	Average Payables
Capex To Operating Cash Flow	- 0.89	Free Cash Flow Yield